At the CPDC, we continue to harvest the potential of radiopharmaceuticals that are generated in our own discovery programs and in collaboration with our academic and pharma partners. Since our inception, our mission has been to increase the number of innovative imaging probes and radiotherapeutics in the clinic, thereby providing both physicians and patients with access to leading-edge technologies that improve patient health.
We believe there are many opportunities to transform unlikely cancer drug candidates to effective therapeutics, by exploiting the unique properties of radiopharmaceuticals. To do this, our strategy is to search for highly target-selective delivery agents that have validated drug targets and have been proven safe in the clinic, but lack the desired efficacy. We seek out partners with those underappreciated assets and then breathe new life into the drug candidates by arming them with a radioactive payload that adds potent cell-killing power to the precision targeting of the delivery agent. What’s more, we can develop an imaging twin to our therapeutic that allows us to see first-hand how the drug accesses the target tissue and understand if the drug is best for certain patients. This strategy, combined with our specialized teams and unique infrastructure, allows us to accelerate radiopharmaceuticals and imaging agents into the clinic and increase their chance of success. CPDC is always eager to discuss our R&D strategy with collaborators, cultivating new opportunities based on this approach.
CPDC has created a for-profit biotech company, Fusion Pharmaceuticals Inc, to spearhead the clinical development and commercialization of promising drug candidates discovered at the CPDC. This includes FPX-01, a phase 1 trial-tested, radioimmunoconjugate that targets the IGF-1R receptor. To learn more about Fusion Pharmaceuticals and FPX-01 please visit www.fusionpharma.com.
We understand that great ideas and great products sometimes need assistance in traversing the translational barrier. Our goals are to help both our academic and pharma partners assess and de-risk their pharmaceutical assets and to turn good ideas into great opportunities. We also know that creating a great opportunity needs a lot of collaborative support. At the CPDC, our experts look at the science, technology, and the regulatory and business environment to make sure we deliver the very best outcomes for our partners.
For us, a new partner relationship begins with discussion of your program, to best understand your vision and goals, and to determine how it aligns with the CPDC’s capabilities. When a collective opportunity is identified, we will work with you to assess and fully understand the scientific and technical aspects of the program and interlace these with the regulatory and business objectives. There are many different arrangements through which we can work with you. We invite you to contact us today to turn your good idea into a great opportunity.
HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD. New investors in the second
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.